



Brain and Spine Tumor Program Clinical Trials

Our Neuro-Oncology Service Promise: Patients can be seen
within 3 business days.

Updated 1.12.11

843.792.6592
www.MUSChealth.com/cancer/neurologicalcancer



Changing What's Possible

<p>Glioblastoma, Adjuvant (1): CTO: 101347</p> <p>BTT08-01: A Phase II study of Bevacizumab and Erlotinib after Radiation Therapy & Temozolomide in patients with newly diagnosed glioblastoma without MGMT promoter methylation.</p> <p>Principal Investigator: Pierre Giglio, MD Tel: 843-792-6592 E-mail: giglio@muscc.edu</p> <p>Study Coordinator: John Keller Tel: 843-792-1286 E-mail: kellej@muscc.edu</p> <p>Coordination Site: Clinical Trials Office (Hollings Cancer Center)</p> <p>Trial Source: Brain Tumor Trials Collaborative/Genetech</p>	<p>Glioblastoma, Adjuvant (2): CTO: 101481</p> <p>RTOG 0837: Randomized, Phase II, Double-Blind, Placebo-Controlled trial of conventional chemoradiation and adjuvant temozolomide plus cediranib versus conventional chemoradiation and adjuvant temozolomide plus placebo in patients with newly diagnosed glioblastoma.</p> <p>Principal Investigator: Pierre Giglio, MD Tel: 843-792-6592 E-mail: giglio@muscc.edu</p> <p>Study Coordinator: John Keller Tel: 843-792-1286 E-mail: kellej@muscc.edu</p> <p>Coordination Site: Clinical Trials Office (Hollings Cancer Center)</p> <p>Trial Source: RTOG 0837</p>	<p>Our Neuro-Oncology Service Promise: Patients can be seen within 3 business days.</p>
<p>Glioblastoma, Recurrent: CTO: 101254</p> <p>A Phase I/II Study of Intraventricular Depocyt (Orphan Drug Designation 06-2348) in Patients with Recurrent Glioblastoma.</p> <p>Principal Investigator: Bruce Frankel, MD Tel: 843-792-2423 E-mail: frankel@muscc.edu</p> <p>Study Coordinator: Michele DeCandio, RN Tel: 843-792-9016 E-mail: decandio@muscc.edu</p> <p>Coordination Site: Translational Research Unit (Neurosciences)</p> <p>Trial Source: NIH Funding</p>	<p>The Effect of Garlic Compounds on Fresh Human Glioma Biopsies: CTO: 101378</p> <p>Principal Investigator: Arabinda Das, PhD E-mail: dasa@muscc.edu</p> <p>Study Coordinator: Michele DeCandio, RN Tel: 843-792-9016 E-mail: decandio@muscc.edu</p> <p>Coordination Site: Translational Research Unit (Neurosciences)</p>	<p>Anaplastic Glioma, Adjuvant (1): CTO: 101450</p> <p>RTOG EORTC 0834/26053 22054, "Phase III Trial on concurrent and adjuvant temozolomide chemotherapy in Non-1p/19q deleted anaplastic glioma."</p> <p>Principal Investigator: Pierre Giglio, MD Tel: 843-792-6592 E-mail: giglio@muscc.edu</p> <p>Study Coordinator: John Keller Tel: 843-792-1286 E-mail: kellej@muscc.edu</p> <p>Coordination Site: Clinical Trials Office (Hollings Cancer Center)</p> <p>Trial Source: The CATNON Intergroup Trial (RTOG 834)</p>
<p>Anaplastic Glioma, Adjuvant (2): CTO: 101449</p> <p>Phase III Intergroup Study of Radiotherapy versus Temozolomide Alone versus Radiotherapy with Concomitant and Adjuvant Temozolomide for Patients with 1p/19q Codeleted Anaplastic Glioma'</p> <p>Principal Investigator: Pierre Giglio, MD Tel: 843-792-6592 E-mail: giglio@muscc.edu</p> <p>Study Coordinator: John Keller Tel: 843-792-1286 E-mail: kellej@muscc.edu</p> <p>Coordination Site: Clinical Trials Office (Hollings Cancer Center)</p> <p>Trial Source: NCCTG</p>	<p>Low Grade Glioma, Progressive: CTO: 101399</p> <p>ECOG E3F05, "Phase III Study of Radiation Therapy With or Without Temozolomide for Symptomatic or Progressive Low-Grade Gliomas."</p> <p>Principal Investigator: Pierre Giglio, MD Tel: 843-792-6592 E-mail: giglio@muscc.edu</p> <p>Study Coordinator: John Keller Tel: 843-792-1286 E-mail: kellej@muscc.edu</p> <p>Coordination Site: Clinical Trials Office (Hollings Cancer Center)</p> <p>Trial Source: ECOG (Study E3F05); RTOG Endorsed</p>	<p>Meningioma, Adjuvant: CTO: 101382</p> <p>Phase II Trial of observation for low-risk meningiomas and of radiotherapy for intermediate and high-risk meningiomas.</p> <p>Principal Investigator: Pierre Giglio, MD Tel: 843-792-6592 E-mail: giglio@muscc.edu</p> <p>Study Coordinator: John Keller Tel: 843-792-1286 E-mail: kellej@muscc.edu</p> <p>Coordination Site: Clinical Trials Office (Hollings Cancer Center)</p> <p>Trial Source: RTOG (RTOG 0539)</p>